- Home
- ALLO
as 02-21-2025 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 427.7M | IPO Year: | 2018 |
| Target Price: | $10.06 | AVG Volume (30 days): | 9.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.32 - $5.78 | Next Earning Date: | 03-13-2025 |
| Revenue: | $43,000 | Revenue Growth: | 26.47% |
| Revenue Growth (this year): | -35.71% | Revenue Growth (next year): | -24.06% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Douglas Earl Martin | ALLO | SVP, General Counsel | Feb 3 '25 | Sell | $1.71 | 6,404 | $10,950.84 | 587,848 | |
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Feb 3 '25 | Sell | $1.73 | 4,361 | $7,544.53 | 1,301,540 | |
| Chang David D | ALLO | President and CEO | Feb 3 '25 | Sell | $1.68 | 46,003 | $77,285.04 | 5,317,237 | |
| MOORE TIMOTHY L. | ALLO | Chief Technical Officer | Feb 3 '25 | Sell | $1.71 | 14,746 | $25,215.66 | 250,713 | |
| Roberts Zachary | ALLO | EVP of R&D | Feb 3 '25 | Sell | $1.70 | 18,832 | $32,014.40 | 643,135 | |
| Roberts Zachary | ALLO | EVP of R&D | Jan 21 '25 | Sell | $1.78 | 27,199 | $48,414.22 | 643,135 | |
| MESSEMER DEBORAH M. | ALLO | Director | Dec 9 '24 | Sell | $2.18 | 9,136 | $19,916.48 | 157,629 | |
| Humer Franz B | ALLO | Director | Dec 5 '24 | Sell | $2.16 | 9,221 | $19,917.36 | 307,507 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
GlobeNewswire
18 days ago
Allogene Therapeutics Announces Participation in February Investor Conferences
Zacks
24 days ago
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
GlobeNewswire
24 days ago
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
MT Newswires
25 days ago
Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate
GlobeNewswire
25 days ago
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Zacks
2 months ago
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Zacks
2 months ago
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.